Early- and advanced non-enzymatic glycation in diabetic vascular complications: the search for therapeutics

Area of Science:

• Endocrinology
• Cardiology
• Biochemistry

Background:

• Cardiovascular disease (CVD) is a major complication and cause of death in diabetic patients.
• Preventing vascular complications is crucial due to high premature morbidity and mortality in diabetes.
• The precise mechanisms of diabetic vascular damage are not fully understood, but non-enzymatic glycation is a suspected contributor.

Purpose of the Study:

• To review the role of non-enzymatic glycation in the development of vascular complications in diabetes.
• To survey data linking Amadori-modified glycated proteins and advanced glycation endproducts (AGEs) to vascular disease.
• To describe recent pharmacological inhibitors targeting glycation pathways.

Main Methods:

• Literature review of studies on non-enzymatic glycation and diabetic vascular complications.
• Survey of data on Amadori products and AGEs in vascular disease.
• Review of recent developments in pharmacological inhibitors of glycation.

Main Results:

• Evidence supports a causal relationship between non-enzymatic glycation and vascular complications in diabetes.
• Amadori-modified glycated proteins and AGEs play a significant role in diabetic vascular disease.
• Pharmacological inhibitors targeting glycation formation or consequences show promise.

Conclusions:

• Non-enzymatic glycation, through early and advanced products, is implicated in diabetic vascular complications.
• Pharmacological interventions aimed at inhibiting glycation may retard the progression of vascular disease in diabetes.
• Further research into glycation pathways and inhibitor development is warranted.